PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy

Inclusion Criteria

• Patients who meet current indications for the CONTAK RENEWAL® family of cardiac resynchronization therapy defibrillator (CRT-D) devices or future Food and Drug Administration (FDA) approved Guidant CRT-D devices
• Patients who sign and date a Patient Informed Consent at, or prior to, the implant visit
• Patients who are in sinus rhythm at the time of implant
• Patients who remain in the clinical care of the enrolling physician in approved centers
• Patients who are on optimal pharmacologic therapy or who have developed a recent implantable cardioverter defibrillator (ICD) indication that necessitates ICD therapy concurrent with the optimization of pharmacologic therapy

Exclusion Criteria

• Patients whose medical condition is expected to preclude the use of the protocol-required pacing mode (dual chamber pacing [DDD or DDDR]) and respective lower rate limits
• Patients with permanent atrial fibrillation or atrial flutter
• Patients who are in complete heart block
• Patients who have previously had a pacemaker, ICD, or CRT device
• Patients whose life expectancy is less than 12 months due to other medical conditions
• Patients who are expected to receive a heart transplant during the duration of the study
• Patients who have other cardiac surgeries or procedures planned but not yet performed
• Patients who currently have or who are likely to receive a tricuspid valve prosthesis
• Patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study.
• Patients who are younger than 18 years of age
• Patients who are mentally incompetent and cannot sign a Patient Informed Consent form or comply with the study
• Patients who are or become pregnant